Key Takeaways
- Vivici has secured EUR 12.5 million from the European Innovation Council (EIC) Accelerator Program to scale market access and supply of its Vivitein™ Ingredient Portfolio of functional protein ingredients.
- The EIC Accelerator is the EU's flagship program for high-impact innovation, selecting a small number of companies per round from a large competitive applicant pool following expert evaluation and interview.
- The award follows the commercialization of Vivici's flagship ingredient Vivitein™ BLG (beta-lactoglobulin) and the recent U.S. launch of Vivitein™ LF (lactoferrin) with self-affirmed GRAS status.
- Both ingredients are produced through precision fermentation, giving health and wellness brands access to high-purity dairy proteins without the supply and cost constraints of traditional production.
- Vivici plans to use the funding to scale supply, expand market access, and accelerate innovation in response to what the company describes as strong customer demand.
Vivici Secures €12.5 Million from EIC Accelerator
Vivici has secured EUR 12.5 million from the European Innovation Council (EIC) Accelerator Program. The award will support the company's plans to scale the market access and supply of its Vivitein™ Ingredient Portfolio of functional protein ingredients and to accelerate innovation for the customers and consumers it serves.
The EIC Accelerator is the European Union's flagship program for high-impact innovation, backing a small number of companies in each round from a large and competitive field of applicants. Vivici was selected following a rigorous evaluation process and an interview before a jury of experienced investors and entrepreneurs.
“Securing the support of the EIC is a powerful endorsement of what we are building at Vivici. It tells us that Europe sees the same opportunity we do, to turn the promise of precision fermentation into a commercial reality, at scale, for the benefit of customers and consumers. This funding allows us to move faster on exactly that,” said Stephan van Sint Fiet, CEO of Vivici.
What the Funding Will Support
The EUR 12.5 million sits within Vivici's wider business plan and will be used to unlock the potential of the company's precision fermentation technology, sustainably scale the market access and supply of its Vivitein™ ingredients, and drive further innovation for customers and consumers.
“Customer demand for our ingredients is already strong, and this backing lets us meet it with the supply and pace the market expects,” said Simon Penfold, Chief Commercial Officer of Vivici.
Vivici's Commercial Momentum with Vivitein™ Ingredients
The award follows a period of rapid commercial progress for Vivici. The company launched its second Vivitein™ ingredient, Vivitein™ LF (lactoferrin), in the U.S. market earlier this year with self-affirmed GRAS status, following the earlier commercialization of its flagship ingredient, Vivitein™ BLG (beta-lactoglobulin).
Both ingredients are produced through precision fermentation, giving health and wellness brands access to high-purity dairy proteins without the supply and cost constraints associated with traditional animal-based production methods.
A Competitive Validation from the EIC
Being selected for EIC Accelerator funding is widely viewed as a strong and credible validation of a company's technology and commercial progress, given the program's selective evaluation process. For Vivici, the award represents a signal of confidence from the European innovation community in the role precision fermentation can play in building a more sustainable food system.
